Filtered By:
Countries: Japan Health
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 5140 results found since Jan 2013.
Dihydroisocoumarins of Hydrangea macrophylla var. thunbergia inhibit binding of the SARS-CoV-2 spike protein to ACE2
In this study, we screened an in-house extract library to identify food materials with inhibitory activity against this binding using enzyme-linked immunosorbent assays and attempted to ascertain their active constituents. Hydrangea macrophylla var. thunbergia leaves were identified as candidate materials. Its active compounds were purified using conventional chromatographic methods and identified as naringenin, dihydroisocoumarins, hydrangenol, and phyllodulcin, which have affinities for angiotensin-converting enzyme 2 receptor and inhibit angiotensin-converting enzyme 2 receptor-spike S1 binding. Given that boiled water ...
Source: Bioscience, Biotechnology, and Biochemistry - June 9, 2023 Category: Biochemistry Authors: Akira Yano Sayaka Yuki Yuko Kanno Akiko Shiraishi Hiroki Onuma Shota Uesugi Source Type: research
Comparison of diet, sleep, and stress during the emergency coronavirus disease curfew in men and women with hemodialysis
To investigate the effect of coronavirus disease 2019 (COVID-19) on diet, stress, and sleep in Japanese patients with hemodialysis.
Source: Journal of Renal Nutrition - June 9, 2023 Category: Urology & Nephrology Authors: Yuka Kawate, Yoshitaka Hashimoto, Shiho Kosaka, Fuyuko Takahashi, Atsuko Sawamura, Yukina Yumen, Masahide Hamaguchi, Masahiro Yamazaki, Michiaki Fukui Tags: Original Research Source Type: research
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
